NCT02427958View on ClinicalTrials.gov

A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants

PHASE4CompletedINTERVENTIONAL
Enrollment

307

Participants

Timeline

Start Date

August 7, 2015

Primary Completion Date

November 23, 2018

Study Completion Date

November 23, 2018

Conditions
Central Precocious Puberty
Interventions
DRUG

Leuprorelin

Suspension for injection.

Trial Locations (9)

Unknown

Beijing

Wuhan

Changsha

Nanjing

Wuxi

Nanchang

Changchun

Shanghai

Hangzhou

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY